Skip navigation

Collaboration, Regulation and Innovation to Reduce the Risk of Addiction, Abuse, Misuse and Overdose

March 13-14, 2018
  • Washington, DC

Now in its fourth year, CBI’s Abuse-Deterrent Formulations Summit is here. The 2018 program continues CBI’s leadership in this space by providing delegates informative and compelling discussions. The panels and presentations will educate participants with the most up-to-date information in this dynamic and rapidly changing field. This year, we are pleased to announce the addition of a workshop offering an in-depth examination of clinical innovations and regulatory challenges of developing Abuse-Deterrent Formulations.

The Top Benefits for Delegates:

  • Learn about the latest FDA guidelines for generics developing ADFs
  • Learn about FDA expectations regarding real-world data and class IV labels
  • Gain a greater understanding of payers and doctors perspective
  • Participate in multi-stakeholder discussion regarding reimbursement

In-Depth Sessions & Discussions Include:

  • How to Achieve Better Market Access
  • FDA Update on Recently Released Policies for Fighting
    the Opioid Epidemic
  • How Insurers are Fighting the Epidemic
  • How Cross-Industry Collaboration can Effectively Address
    Addiction and Abuse
  • Who Should Get ADFs —
    Identify the Appropriate Demographic and Disease State for ADFs
  • Provider Networks Current and Desired Paths for
    Working with Pharma and Treating Addiction and Abuse
  • Multi-Stakeholder Panel on ROI

Download the Conference Preview

Previous Attendee Acclaim:

Excellent conference. Organizers did a great job
of coming up with unique talks.

VP, Regulatory Affairs, KemPharm

Great opportunity to network and learn about new label developments in the field of ADF from multiple stakeholders.

Int. Tech. Project Leader, Grünenthal

Good content; not repetitive; keep including FDA.

CCO, Alcobra

Abuse-Deterrent Formulations Summit

Collaboration, Regulation and Innovation to Reduce the Risk of Addiction, Abuse, Misuse and Overdose

Now in its fourth year, CBI’s Abuse-Deterrent Formulations Summit is here. The 2018 program continues CBI’s leadership in this space by providing delegates informative and compelling discussions. The panels and presentations will educate participants with the most up-to-date information in this dynamic and rapidly changing field. This year, we are pleased to announce the addition of a workshop offering an in-depth examination of clinical innovations and regulatory challenges of developing Abuse-Deterrent Formulations.

The Top Benefits for Delegates:

  • Learn about the latest FDA guidelines for generics developing ADFs
  • Learn about FDA expectations regarding real-world data and class IV labels
  • Gain a greater understanding of payers and doctors perspective
  • Participate in multi-stakeholder discussion regarding reimbursement

In-Depth Sessions & Discussions Include:

  • How to Achieve Better Market Access
  • FDA Update on Recently Released Policies for Fighting
    the Opioid Epidemic
  • How Insurers are Fighting the Epidemic
  • How Cross-Industry Collaboration can Effectively Address
    Addiction and Abuse
  • Who Should Get ADFs —
    Identify the Appropriate Demographic and Disease State for ADFs
  • Provider Networks Current and Desired Paths for
    Working with Pharma and Treating Addiction and Abuse
  • Multi-Stakeholder Panel on ROI

Download the Conference Preview

Previous Attendee Acclaim:

Excellent conference. Organizers did a great job
of coming up with unique talks.

VP, Regulatory Affairs, KemPharm

Great opportunity to network and learn about new label developments in the field of ADF from multiple stakeholders.

Int. Tech. Project Leader, Grünenthal

Good content; not repetitive; keep including FDA.

CCO, Alcobra